A spinout from the University of Cambridge which produces medical treatments for horses and livestock will announce this week a collection of funds of nearly 5 million pounds sterling with a union of high -level shareholders.
Sky News understands that Nobacz Healthcare has obtained the capital of donors led by the return, an investor specializing in European agriculture and food technology companies.
Adjuvo, The Angel Investor Network, ACF Investors, Cambridge University, Parkwalk, the FSE group and Cambridge Enterprise Ventures also participated in the round of 4.8 million pounds sterling.
Nobacz has developed a range of so-called liquid bandage technology for farm animals, which aims to usurp the use of antibiotics and fabric bandages, which can often be contaminated in agricultural environments.
The company was founded by Dr. Jonathan Powell and Dr Nuno Faria, whose research in the Cambridge Veterinary Medicine Department examined how the body naturally built and uses mineral structures for its own advantage.
Their product was initially developed to treat digital dermatitis, which affects a quarter of the cows.
Dr. Powell, managing director of Nobacz, said: “We have founded Nobacz Healthcare in order to transform health care solutions for a more sustainable future while reducing the use of antibiotics.
“This new funding will feed our expansion while we expand our global product range, will launch our new range of products for the equine industry and continue to develop innovative veterinary health solutions.”
He added that in addition to its pipeline of veterinary products, the company “began to define our opportunity for human product”.
Mark Foster-Brown, CEO of Adjuvo, said: “For too long, antibiotics and topical bandages have offered inadequate solutions for animal wound care.
“Nobacz’s patented platform technology establishes a new reference, providing revolutionary results while aligning with the Adjuvo mission to support innovation in the poorly serving sectors.”